TOMI Environmental Solutions, Inc. (TOMZ) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. TOMI Environmental Solutions, Inc. is a global provider of disinfection and decontamination essentials using its Binary Ionization Technology (BIT) platform, primarily under the SteraMist brand. The company operates in four divisions: Life Sciences, Hospital Healthcare, Food Safety, and Commercial. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $1,031,115 | $3,013,392 | $2,607,673 | $4,127,479 |
| Gross Profit | $677,124 | $1,854,516 | $1,628,869 | $2,525,184 |
| Gross Margin | 66% | 62% | 62% | 61% |
| Net Loss | $(1,237,516) | $30,198 (Income) | $(1,493,109) | $(1,279,992) |
| Operating Cash Flow | N/A | N/A | $(463,302) | $(1,558,173) |
| Cash & Equivalents | $569,450 | N/A | $569,450 | $709,110 |
| Working Capital | $2,809,688 | N/A | $2,809,688 | $3,772,203 |
| Convertible Debt (Net) | $2,781,730 | N/A | $2,781,730 | $2,360,494 |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2025 revenue decreased 66% year-over-year to $1.03 million. Management attributes this to customers deferring capital expenditure projects due to economic uncertainty and announced tariffs impacting supply chains. Product revenue dropped 76%, while service revenue increased 33%.
- Profitability: The company reported a net loss of $1.24 million for Q2 2025, compared to a net income of $30,000 in Q2 2024. Operating expenses increased slightly by 4% ($77,000) due to higher professional fees, offset by reduced selling expenses.
- Unusual Items: The YTD 2025 results include a one-time benefit of $534,912 in Employee Retention Credits (ERC) recorded as "Other Income," which significantly reduced the YTD net loss compared to operating performance.
- Debt Issuance: The company raised $435,000 in gross proceeds from the issuance of convertible notes during the first six months of 2025.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year due to recurring losses, negative cash flows, and an accumulated deficit of $55.8 million. The company intends to fund operations through existing cash, operational cash flow, and additional equity or debt financing.
- Backlog and Pipeline: As of June 30, 2025, the sales order backlog was approximately $1.4 million. Management is negotiating approximately $2 million in new custom contracts expected to close by year-end. Service revenue quotes are up 35% year-over-year.
- Internal Controls: The company identified a material weakness in internal control over financial reporting due to limited resources in the finance department and ineffective policies for reviewing accounting functions. A new CFO was appointed in May 2025 to assist with remediation.
- Market Risks: Revenue is sensitive to global health outbreaks, sales cycle length, and distributor timing. The company relies on a small number of customers for a significant portion of revenue (one customer accounted for 10% of Q2 revenue).
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $569,450 cash balance against the burn rate and the likelihood of securing additional financing given the "Going Concern" warning.
- Revenue Quality: Assess the sustainability of the 33% growth in service revenue versus the 76% decline in product revenue, and the impact of tariffs on future capital projects.
- Debt Obligations: Review the terms of the $3.035 million in convertible notes (12% interest, conversion price $1.25) and the potential for dilution upon conversion.
- Internal Controls: Monitor the progress of remediation plans for the material weakness in financial reporting controls.
- Customer Concentration: Evaluate the risk associated with reliance on a few key customers and distributors (e.g., ARES Distribution, Avantor Sciences).